British pharmaceutical company GlaxoSmithKline on Wednesday said its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...

The UK drugmaker’s best-selling shingles shot Shingrix as well as specialty medicines including drugs for asthma, HIV and ...

GSK lifted profit guidance for the year on Wednesday after sales of the drugmaker's 'specialty' medicines soared.

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core ...

Revenue in the second quarter of 2025 rose 1.3% to GBP7.99 billion from GBP7.88 billion, helping to push pretax profit up 26% to GBP1.89 billion from GBP1.50 billion. Core operating profit rose 12% at ...

(Reuters) -British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after ...

The FTSE 100 (^FTSE) and European stocks slipped on Wednesday morning as traders digest a slew of earnings reports in London, ...

Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...